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抗体（DAKO, USA） にはLSAB kit （DAKO）で，抗グル
カゴン抗体・抗ソマトスタチン抗体・抗PP抗体
（DAKO）の混合抗体はABC AP kit （Vector, USA）を用
いて二重染色を行った．染色後，各切片はOlympus 
（Tokyo）およびCCDカメラ （Olympus, Tokyo）とPower 
PC 6100 （Macintosh, USA）を結んで画像を取り込み，






104/wellを 96 wellマルチプレート（Iwaki, Japan）にま
き，FCS （－） DMEM （Sigma, USA）（5.6 mM glucose






















Effects of Troglitazone on Pancreatic Islet  Cell Proliferation
Nobuyoshi Tane, Chikara Ishii, Kiyohiko Negishi, Shigehiro Katayama (Fourth Department of Internal Medicine, 
Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan)
The effect of Troglitazone (Tro) on the proliferation of Wistar rat pancreatic islet  cells was evaluated 
immunohistologically. The rats were divided into a standard-diet group (control group, n9), a fructose-
containing diet group (FRU group, n8), and a fructose-containing diet plus Troglitazone (70 mg/kg, per 
os) group (Tro group, n9). In the Tro group, the pancreatic islet  cell area determined by imuunological 
staining using a specific antibody against rat insulin was significantly lower in comparison with the control and 
FRU group. To elucidate the mechanisms, Tro was added to cultured MIN6 cells. Tro (0.2, 2, and 20 g/ml) 
significantly and dose-dependently reduced the BrdU-labeled MIN6 cell number without affecting cell viability. 
Prolactin (PRL) increased the number of BrdU-labeled cells 1.7-times as compared to the controls, which was 
decreased by adding 2 g/ml of Tro, while phorbor myristate acetate (PMA) did not affect the BrdU-labeled cell 
number. These results suggest the possibility that Tro inhibits pancreatic islet  cell proliferation mainly through 
blocking the system mediated via PRL receptors (JAK-STAT system).
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1） BrdU標識量に対するTroの影響：Tro 0.2, 2, 20 g/ml
を含む培養液で 24, 48, 72, 144, 168時間培養し，Biotrack 
Cell Proliferation Kit （Amersham, USA）を用いてBrdUを
4時間標識し，ELIZA （450 nm）にて標識量を測定した
（各n＝12）．
2） Troの細胞毒性についての検討：MIN6をTro 0.2, 2, 
20 g/mlを含む培養液にて 24時間培養後，通常の方
法に従って 3-（4,5-dimethylthiazol-2-yl）-2,5 tetrazolium 





Platelet-derived growth factor （PDGF;2, 20, 200 ng/ml,
各n＝12），Phorbol 12- myristate 13- acetate （PMA; 10-8, 






























Fig. 2. Effect of Troglitazone on BrdU-labeled cell count. A 
significant dose-dependent decrease was observed at 24, 48 and 168 
hours.  At 72 and 144 hours, 2 and/or 20 g/ml of Troglitazone 
significantly decreased BrdU-labeled cell count. ( P0.01, P0.001 
vs. controls)
Fig. 3. Effect of Troglitazone on MIN6 cell viability. After 24 hours, 
cell viability was the same as in the controls at every Troglitazone 
concentration.
Fig. 1.  cell mass: In the Tro group (n8), the pancreatic  cell 
area determined by immunostaining using a specific antibody against 
insulin was significantly lower in comparison with the control group 




















































Fig. 4. Effect of PDGF with or without Troglitazone on MIN6 
proliferation. A significant increase in BrdU-labeled cell count was 
observed only when 2 ng/ml of PDGF was added. When 4 g/ml 
of Troglitazone was added, PDGF-induced increase in BrdU-labeled 
cell count was significantly suppressed. ( P0.05, P0.001 vs. 
controls)
Fig. 6. Effect of PRL with or without Troglitazone on MIN6 
proliferation. PRL significantly increased the BrdU labeled MIN6 cell 
count 1.7 times as compared to controls. However, the addition of 
Troglitazone (2 g/ml) significantly suppressed PRL-induced increase 
in the cell count to the same level as in controls. 
(P0.001 vs. controls, #P0.001 vs. PRL) 
Fig. 5. Effect of PMA with or without Troglitazone on MIN6 
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